Cargando…

Similar Clinical Outcomes of Early and Late Anti-TNF Initiation for Ulcerative Colitis: A Nationwide Population-Based Study

PURPOSE: The optimal timing of anti-tumor necrosis factor (anti-TNF) initiation in patients with ulcerative colitis (UC) remains unclear. Very little is known about the clinical outcomes after the early versus late initiation of anti-TNF therapy, especially in Asian UC patients. Here we aimed to ass...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Minkyung, Jung, Yoon Suk, Cheon, Jae Hee, Park, Sohee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Yonsei University College of Medicine 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214112/ https://www.ncbi.nlm.nih.gov/pubmed/32390361 http://dx.doi.org/10.3349/ymj.2020.61.5.382

Ejemplares similares

Impact of early anti-TNF use on clinical outcomes in Crohn’s disease: a nationwide population-based study
por: Jung, Yoon Suk, et al.
Publicado: (2020)

Comparison of Real-World Outcomes of Infliximab versus Adalimumab in Biologic-Naïve Korean Patients with Ulcerative Colitis: A Population-Based Study
por: Han, Minkyung, et al.
Publicado: (2020)

Cancer Risk in Patients with Intestinal Behçet’s Disease: A Nationwide Population-Based Study
por: Han, Minkyung, et al.
Publicado: (2018)

Cancer risk in Korean patients with Behçet’s disease: A nationwide population-based study
por: Jung, Yoon Suk, et al.
Publicado: (2017)

Similar Clinical and Surgical Outcomes Achieved with Early Compared to Late Anti-TNF Induction in Mild-to-Moderate Ulcerative Colitis: A Retrospective Cohort Study
por: Ma, Christopher, et al.
Publicado: (2016)

Comparison of Long-term Outcomes of Infliximab versus Adalimumab in 1,488 Biologic-Naive Korean Patients with Crohn’s Disease
por: Jung, Yoon Suk, et al.
Publicado: (2021)

Comparing Patient-Reported Outcomes Among Anti-TNF Experienced Patients With Ulcerative Colitis Initiating Vedolizumab Versus Tofacitinib
por: Kappelman, Michael D, et al.
Publicado: (2023)

Anti-TNF-Related Leukocytoclastic Vasculitis in Ulcerative Colitis: A Case Report
por: Giorgio, Valentina, et al.
Publicado: (2021)

Understanding the Role of Adalimumab in the Treatment of Moderately to Severely Active Ulcerative Colitis
por: Kim, Jae Hyun, et al.
Publicado: (2016)

Clinical Efficacy of Beclomethasone Dipropionate in Korean Patients with Ulcerative Colitis
por: Lee, Yoon Jee, et al.
Publicado: (2017)

Ulcerative Colitis and Crohn's Disease: Similarities and Distinctions
por: Sawyerr, Af M, et al.
Publicado: (1994)

Unmet Psychosocial Needs of Patients with Newly Diagnosed Ulcerative Colitis: Results from the Nationwide Prospective Cohort Study in Korea
por: Moon, Jung Rock, et al.
Publicado: (2020)

A Clinical Significance of Assessing Cytomegalovirus Infection Status in Patients With Ulcerative Colitis
por: Chang, Sooyun, et al.
Publicado: (2015)

Changes in fecal metabolic and lipidomic features by anti-TNF treatment and prediction of clinical remission in patients with ulcerative colitis
por: Kim, Seok-Young, et al.
Publicado: (2023)

Corrigendum: Unmet Psychosocial Needs of Patients Newly Diagnosed with Ulcerative Colitis: Results from the Nationwide Prospective Cohort Study in Korea
por: Moon, Jung Rock, et al.
Publicado: (2021)

Prognostic Value of Terminal Ileal Inflammation in Patients with Ulcerative Colitis
por: Yu, Jongwook, et al.
Publicado: (2021)

Could Mucosal TNF Transcript as a Biomarker Candidate Help Optimize Anti-TNF Biological Therapy in Patients With Ulcerative Colitis?
por: Cui, Guanglin, et al.
Publicado: (2022)

Pyroptosis-Related Signature Predicts the Progression of Ulcerative Colitis and Colitis-Associated Colorectal Cancer as well as the Anti-TNF Therapeutic Response
por: Ning, Yumei, et al.
Publicado: (2023)

Identifying anti-TNF response biomarkers in ulcerative colitis using a diffusion-based signalling model
por: Singh, Amrinder, et al.
Publicado: (2021)

Improvement in Medication Adherence after Pharmacist Intervention Is Associated with Favorable Clinical Outcomes in Patients with Ulcerative Colitis
por: Kim, Jae Song, et al.
Publicado: (2022)

Prediction of anti-TNF therapy failure in ulcerative colitis patients by ensemble machine learning: A prospective study
por: Derakhshan Nazari, Mohammad Hossein, et al.
Publicado: (2023)

Two-year delay in ulcerative colitis diagnosis is associated with anti-tumor necrosis factor alpha use
por: Kang, Ho Suk, et al.
Publicado: (2019)

Fecal Immunochemical Test and Fecal Calprotectin Measurement Are Noninvasive Monitoring Tools for Predicting Endoscopic Activity in Patients with Ulcerative Colitis
por: Chang, Ji Young, et al.
Publicado: (2018)

Clinical importance of weight gain and associated factors in patients with moderate to severe ulcerative colitis: results from the MOSAIK cohort in Korea
por: Yoon, Hyuk, et al.
Publicado: (2023)

Biologics in the management of ulcerative colitis – comparative safety and efficacy of TNF-α antagonists
por: Fausel, Rebecca, et al.
Publicado: (2015)

Intestinal Microbiota and Gene Expression Reveal Similarity and Dissimilarity Between Immune-Mediated Colitis and Ulcerative Colitis
por: Sakai, Kazuko, et al.
Publicado: (2021)

Mitochondrial dysfunction-associated microbiota establishes a transmissible refractory response to anti-TNF therapy during ulcerative colitis
por: Peña-Cearra, Ainize, et al.
Publicado: (2023)

Could Chronic Rhinosinusitis Increase the Risk of Ulcerative Colitis? A Nationwide Cohort Study
por: Lee, Il Hwan, et al.
Publicado: (2022)

Evaluation of anti-ulcer and ulcerative colitis of Sonchus oleraceus L
por: Alothman, Esraa A., et al.
Publicado: (2018)

Effects of anti-TNF-α in experimental diversion colitis
por: Buanaim, Ronaldo Parisi, et al.
Publicado: (2019)

Comparison of Long-term Outcomes of Infliximab versus Adalimumab Treatment in Biologic-Naïve Patients with Ulcerative Colitis
por: Lee, Yong Il, et al.
Publicado: (2021)

Comparative effectiveness of second-line biological therapies for ulcerative colitis and Crohn’s disease in patients with prior failure of anti-tumour necrosis factor treatment
por: Hyun, Hye Kyung, et al.
Publicado: (2022)

Cerebral Venous Thrombosis as an Initial Presentation of Ulcerative Colitis
por: Yamazaki, Hiroshi, et al.
Publicado: (2022)

Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-α
por: Park, Jihye, et al.
Publicado: (2022)

Real World Effectiveness of Golimumab Therapy in Ulcerative Colitis Regardless of Prior TNF Exposure
por: Bressler, Brian, et al.
Publicado: (2018)

Contribution of NOTCH signaling pathway along with TNF-α in the intestinal inflammation of ulcerative colitis
por: Ghorbaninejad, Mahsa, et al.
Publicado: (2019)

Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan
por: Hernandez, Luis, et al.
Publicado: (2019)

Cost-Effectiveness Analysis of Vedolizumab Compared With Infliximab in Anti-TNF-α-Naïve Patients With Moderate-to-Severe Ulcerative Colitis in China
por: Zhou, Ting, et al.
Publicado: (2021)

Late relapse of ulcerative colitis presenting as tracheobronchitis: a case report
por: Okamoto, Shouichi, et al.
Publicado: (2022)

Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry
por: Biemans, Vince B. C., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_cpb1ctk5jh2ad71l45p57d1vqr